Suchergebnisse - "Babak, Maria V"

PubPharm (11)

1

Synthesis, structural characterization and anticancer properties of p-cymene Ru(II) complexes with 2-(N-methyl-1H-1,2,4-triazol-3-yl)pyridines

enthalten in: Transition metal chemistry | 2022

von Ohorodnik, Y. | Alexander, S. | Khomenko, D. | +5

2

Synthesis and Evaluation of Biological Activity of Homodrimane Sesquiterpenoids Bearing Hydrazinecarbothioamide or 1,2,4-Triazole Unit

enthalten in: Chemistry of heterocyclic compounds | 2019

von Lungu, L. | Ciocarlan, A. | Barba, A. | +9

3

Copper(ii) thiosemicarbazone complexes induce marked ROS accumulation and promote nrf2-mediated antioxidant response in highly resistant breast cancer cellsElectronic supplementary information (ESI) available: ORTEP view of crystal structures of 1′ with atom labeling schemes and thermal ellipsoids drawn at 50% probability level (Fig. S1), dependence of absorbance vs. pH, concentration of the proligand, concentration of copper(ii) and calibration curve for the copper(ii)-NaH2LH system, competition with EDTA at λ = 375 nm (Fig. S2-S6), details of the crystal structures of 1, 2, 1′ and 3 (Fig. S7-S11), concentration-effect curves (Fig. S12), crystal data and details of data collection, bond lengths and angles in 1, 2 and 1′, 3 (Tables S1-S3). CCDC 1497276-1497279. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c7dt00283a

enthalten in: Dalton transactions | 2017

von Sîrbu, A. | Palamarciuc, O. | Babak, M. | +8

4

The development of RAPTA compounds for the treatment of tumors

enthalten in: Coordination chemistry reviews | 2016

von Murray, B. | Babak, M. | Hartinger, C. | +1

5

Structural Determinants of p53-Independence in Anticancer Ruthenium-Arene Schiff-Base Complexes

enthalten in: Molecular pharmaceutics | 2016

von Chow, M. | Babak, M. | Wong, D. | +3

6

Half‐Sandwich Ruthenium(II) Biotin Conjugates as Biological Vectors to Cancer Cells

enthalten in: Chemistry - a European journal | 2015

von Babak, M. | Plażuk, D. | Meier, S. | +10

7

Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action

enthalten in: Chem.Sci. | 2015

von Babak, M. | Meier, S. | Huber, K. | +13

8

Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of actionElectronic supplementary information (ESI) available: Experimental, crystallographic, biological and mass spectrometric data, full list of proteins detected by chemical proteomics. CCDC 972667 and 972668. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c4sc03905j

enthalten in: Chem.Sci. | 2015

von Babak, M. | Meier, S. | Huber, K. | +13

9

Development of anticancer agents: wizardry with osmium

enthalten in: Drug discovery today | 2014

von Hanif, M. | Babak, M. | Hartinger, C.

10

Am(m)ines Make the Difference: Organoruthenium Am(m)ine Complexes and Their Chemistry in Anticancer Drug Development

enthalten in: Chemistry - a European journal | 2013

von Babak, M. | Meier , S. | Legin, A. | +5